Fresh warnings from a US congressional advisory body about the rapid rise of China’s biopharmaceutical sector are fuelling Washington’s push to curb cross-border ties, analysts said, though China’s industry appears largely unfazed. China was gaining a “competitive advantage” in biopharmaceuticals, and Western firms were increasingly paying large upfront fees to license Chinese drugs thanks to the country’s “growing innovative capacity”, the US-China Economic and Security Review Commission (USCC)...
Read full article